A new analysis from the National Security Commission on Emerging Biotechnology warns that China is strategically consolidating control over the entire drug supply chain. This move, driven by significant investments from Western pharmaceutical giants into Chinese biotechs, risks making the U.S. dependent on China for future critical treatments. The commission highlights that China's proposed export restrictions on technologies like cell and gene therapy, coupled with increasing licensing agreements that redirect U.S. capital and expertise, could mirror past successes in other industries where China gained market leverage. AI
RANK_REASON Policy analysis from a government commission detailing national security risks related to foreign control of critical supply chains. [lever_c_demoted from significant: ic=1 ai=0.1]
- AstraZeneca
- Axios Technology
- Bristol Myers Squibb
- Brookings Institution
- Caitlin Frazer
- China
- Marta Wosińska
- National Security Commission on Emerging Biotechnology
- Pfizer
- U.S.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →